Thank you to our speakers, sponsors, and delegates who joined us in Boston! If you are interested in the 2025 event, please get in touch at: info@hansonwade.com

Fast-Track Your mRNA-Based Vaccines & Therapeutics from Discovery to Commercialization by Ensuring Targeted Delivery, Durability & Tolerable Immunogenicity Across All Disease Indications

2024 EVENT GUIDE
REGISTER INTEREST
PARTNER

The World’s Largest Industry-Dedicated Gathering for mRNA Professionals

The world's first non-COVID mRNA approval from Moderna has spurred a new wave of candidates moving into early- to late-stage clinical development for rare, infectious and oncological indications. With tremendous strides in the industry, the 4th mRNA-Based Therapeutics Summit cemented its position as the world's largest, end-to-end mRNA conference, bringing attendees exclusive scientific and strategic insights from the biggest players across indications and modalities.

DOWNLOAD THE 2024 AGENDA

In July, 375+ mRNA experts and enthusiasts hears previously-unseen data insights from 65+ world-class speakers from the likes of CureVac, Moderna, BioNTech and Sanofi, and gained exclusive regulatory insights from the FDA, MHRA and EMA.

Attendees personalized their experience and selected which sessions best applied to them, by navigating through 4 tracks of content catering to discovery, translation, clinical development and chemistry, manufacturing and controls. In addition, they joined interactive roundtables and a CXOs’ Panel Discussion, choosing from the Regulatory Affairs Strategy or Next Generation mRNA Delivery focus days.

A Snapshot of the 2024 Speaker Faculty

Carla Vinals - Speaker

Carla Vinals

Vice President, Global Regulatory Product Strategy

Moderna

Kumar Namdev - Speaker

Kumar Namdev

Global Head of CMC Product Development & Industrialization

Sanofi

Nazia Noor - Speaker

Nazia Noor

VP Global Regulatory Affairs, CMC

BioNTech New Data!

Peter Marks - Speaker

Peter Marks

Director

US Food & Drug Administration (FDA)

Sean Sullivan

Vice President, Head of Technology Innovation

Arcturus Therapeutics

Thaminda Ramanayake

Chief Business Officer

CureVac

FDA - 2024 Testimonial

"This was an opportunity to better understand the industry’s needs, and explain the FDA’s expectations.”
Peter Marks, Director CBER

2024 Highlights:

375+

Attendees from Biopharma & Academia

65+

World-Class Speakers

24+

C-Level
Speakers

10+

Hours of In-Person Networking

4

Dedicated Tracks of Content

2

Pre-Conference Focus Days

1

CXOs' Panel Discussion

Lead Partner 2024

Industry Partner 2024

Expertise Partners 2024

FULL LIST OF 2024 PARTNERS
2024 EVENT GUIDE
REGISTER INTEREST
PARTNER